Takeda Pharmaceutical (TAK) Cash from Operations (2018 - 2026)

Takeda Pharmaceutical's Cash from Operations history runs 9 years deep, the most recent figure standing at 1575581736.62 for Q1 2026.

• On a quarterly basis, Cash from Operations rose 8.2% year-over-year to 1575581736.62 in Q1 2026; TTM through Mar 2026 was 8056689657.0, a 15.79% increase from a year earlier, with the FY2026 full-year figure at 8064779691.9, up 16.2% from the prior year.
• Cash from Operations retreated to 1575581736.62 in Q1 2026 per TAK's latest filing, from 2425354411.72 in the prior quarter.
• Across five years, Cash from Operations topped out at 3231846931.85 in Q1 2022 and bottomed at 651383776.08 in Q2 2022.
• The 5-year median for Cash from Operations is 1600108410.1 (2022), against an average of 1783399603.7.
• Across the five-year window, Cash from Operations plunged 62.99% in 2023 and jumped 154.78% in 2024, its largest moves.
• Year by year, Cash from Operations stood at 2677225361.33 in 2022, then plunged by 62.99% to 990775096.48 in 2023, then jumped by 154.78% to 2524260483.73 in 2024, then dropped by 3.92% to 2425354411.72 in 2025, then tumbled by 35.04% to 1575581736.62 in 2026.
• Per Business Quant, the three latest TAK Cash from Operations figures stand at 1575581736.62 (Q1 2026), 2425354411.72 (Q4 2025), and 2566942324.35 (Q3 2025).